Quality Oversight

The Food and Drug Administration is evaluating Chinese-made plastic syringes used to inject or withdraw fluids from the body, citing concern that they may not provide adequate quality and performance, including their ability to deliver the correct dose of medication when used alone or with other…
The latest revisions to the Centers for Medicare & Medicaid Services’ Quality Assurance and Performance Improvement program underscore the integral role of board members in advancing quality improvement initiatives, writes Sue Ellen Wagner, AHA’s vice president of trustee engagement and strategy.
We write to endorse the Value in Health Care Act of 2023. This bipartisan legislation makes several important reforms to ensure that alternative payment models (APMs) continue to produce high quality care for the Medicare program and its beneficiaries.
The Food and Drug Administration today finalized a 2019 proposed rule updating requirements under the Mammography Quality Standards Act of 1992, which authorized FDA oversight of mammography facilities.
AHA provides feedback on the Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S.4348).
The blanket data reporting exceptions and extensions implemented in March across Medicare quality reporting and value-based payment programs for hospitals expired July 1.
Beginning in March, the Centers for Medicare & Medicaid Services will implement a streamlined survey and certification process for psychiatric hospitals, the agency announced today.
The Centers for Medicare & Medicaid Services has issued corrected preview reports for the Discharge to Community measure in the Long-term Care Hospital Quality Reporting Program for review before the data is added to the LTCH Compare website in October.